

Datasheet: MCA1044A647

Description:	RAT ANTI DOG MHC CLASS II MONOMORPHIC:Alexa Fluor® 647
Specificity:	MHC CLASS II MONOMORPHIC
Format:	ALEXA FLUOR® 647
Product Type:	Monoclonal Antibody
Clone:	YKIX334.2
Isotype:	IgG2a
Quantity:	100 TESTS/1ml

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat - 1/10

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

Target Species	Dog		
Species Cross Reactivity	Does not react with:Hooded Seal		
Product Form	Purified IgG conjugated to Alexa Fluor 647 - liquid		
Max Ex/Em	Fluorophore	Excitation Max (nm)	Emission Max (nm)
	Alexa Fluor®647	650	665
Preparation	Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant		
Buffer Solution	Phosphate buffered saline		
Preservative	0.09% sodium azide (NaN ₃)		
Stabilisers	1% bovine serum albumin		
Approx. Protein	IgG concentration 0.05 mg/ml		

Concentrations

Immunogen Con A activated canine peripheral blood cells.

Fusion Partners Spleen cells from immunized DA rats were fused with cells of the rat Y3/Ag1.2.3 myeloma cell line.

Specificity **Rat anti Dog MHC Class II Monomorphic antibody, clone YKIX334.2** recognizes a monomorphic epitope on canine MHC Class II and was classified at the First Canine Leucocyte Antigen Workshop ([Cobbold et al. 1994](#)). The major histocompatibility complex (MHC) is a cluster of genes that are important in the immune response to infections. In dogs, this is referred to as the dog leukocyte antigen (DLA) region. Rat anti Dog MHC Class II immunoprecipitates an antigen of ~32/34 kDa and blocks the proliferation of MHC Class II dependent responses *in vitro*. In dogs, MHC Class II is expressed by all peripheral blood mononuclear cells.

Flow Cytometry Use 10µl of the suggested working dilution to label 10⁶ cells in 100µl

References

1. Cobbold, S. & Metcalfe, S. (1994) Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW). [Tissue Antigens. 43 \(3\): 137-54.](#)
2. Watson, C.J. et al. (1994) Immunosuppression of canine renal allograft recipients by CD4 and CD8 monoclonal antibodies. [Tissue Antigens. 43 \(3\): 155-62.](#)
3. Liu, Y. et al. (2000) Immunosuppressant-free allotransplantation of the trachea The antigenicity of tracheal grafts can be reduced by removing the epithelium and mixed glands from the graft by detergent treatment. [J Thorac Cardiovasc Surg. 120: 108-14.](#)
4. Sanchez, M.A. et al. (2004) Organ-specific immunity in canine visceral leishmaniasis: analysis of symptomatic and asymptomatic dogs naturally infected with *Leishmania chagasi*. [Am J Trop Med Hyg. 70: 618-24.](#)
5. Reis, A.B. et al. (2006) Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by *Leishmania chagasi*. [Clin Exp Immunol. 146: 303-11.](#)
6. Bonnefont-Rebeix, C. et al. (2007) Toll-like receptor 3 (TLR3): a new marker of canine monocytes-derived dendritic cells (cMo-DC). [Vet Immunol Immunopathol. 2007 Jul 15;118\(1-2\):134-9.](#)
7. Schütze, N. et al. (2009) Inactivated parapoxvirus ovis activates canine blood phagocytes and T lymphocytes. [Vet Microbiol. 137: 260-7.](#)
8. Bund, D. et al. (2010) Canine-DCs using different serum-free methods as an approach to provide an animal-model for immunotherapeutic strategies. [Cell Immunol. 263: 88-98.](#)
9. Mito, K. et al. (2010) IFNγ markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models. [Cancer Res. 70: 7093-101.](#)
10. Araújo, M.S. et al. (2011) Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis. [Vet Immunol Immunopathol. 141: 64-75.](#)
11. Larsen, A.K. et al. (2013) Entry and elimination of marine mammal *Brucella* spp. by hooded seal (*Cystophora cristata*) alveolar macrophages *in vitro*. [PLoS One. 8: e70186.](#)
12. Lin, S-C. et al. (2014) Immune Characterization of Peripheral Blood Mononuclear cells of the Dogs Restored from Inoculation of Canine Transmissible Venereal Tumor Cells.

[Tai Vet J. 40 \(04\): 181-90.](#)

13. Constantinoiu, C.C. *et al.* (2015) Mucosal tolerance of the hookworm *Ancylostoma caninum* in the gut of naturally infected wild dogs. [Parasite Immunol. 37 \(10\): 510-20.](#)
14. Bonnefont-Rebeix, C. *et al.* (2016) Characterization of a novel canine T-cell line established from a spontaneously occurring aggressive T-cell lymphoma with large granular cell morphology. [Immunobiology. 221 \(1\): 12-22.](#)
15. Lu, T. *et al.* (2017) Effects of cryopreservation on tracheal allograft antigenicity in dogs. [J Thorac Dis. 9 \(7\): 2038-2047.](#)
16. Reineking, W. *et al.* (2018) Canine primary jejunal and colonic epithelial cells predominantly express TLR5 and TLR9 but do not change TLR expression pattern after stimulation with certain Toll-like receptor ligands. [Vet Immunol Immunopathol. 206: 16-24.](#)
17. Martini, V. *et al.* (2019) Prognostic role of non-neoplastic lymphocytes in lymph node aspirates from dogs with diffuse large B-cell lymphoma treated with chemo-immunotherapy. [Res Vet Sci. 125: 130-5.](#)
18. Grudzien, M. *et al.* (2021) A newly established canine NK-type cell line and its cytotoxic properties. [Vet Comp Oncol. 19 \(3\): 567-77.](#)
19. Bragato, J.P. *et al.* (2022) miRNA-21 regulates CD69 and IL-10 expression in canine leishmaniasis. [PLoS One. 17 \(3\): e0265192.](#)
20. Riccardo, F. *et al.* (2022) Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial. [J Immunother Cancer. 10 \(5\): e004007.](#)
21. Jaensch, S.M. *et al.* (2022) Clinicopathologic and immunophenotypic features in dogs with presumptive large granular lymphocyte leukaemia. [Aust Vet J. 100 \(11\): 527-32.](#)
22. Yang, V.K. *et al.* (2021) Intravenous administration of allogeneic Wharton jelly-derived mesenchymal stem cells for treatment of dogs with congestive heart failure secondary to myxomatous mitral valve disease. [Am J Vet Res. 82 \(6\): 487-93.](#)
23. Crain, S.K. *et al.* (2019) Extracellular Vesicles from Wharton's Jelly Mesenchymal Stem Cells Suppress CD4 Expressing T Cells Through Transforming Growth Factor Beta and Adenosine Signaling in a Canine Model. [Stem Cells Dev. 28 \(3\): 212-26.](#)
24. Martini, V. *et al.* (2018) A retrospective study of flow cytometric characterization of suspected extranodal lymphomas in dogs. [J Vet Diagn Invest. 30 \(6\): 830-6.](#)
25. Sainz, Á. *et al.* (2021) Effect of chemically modified tetracycline-8 (CMT-8) on hematology, blood chemistry, cytokines and peripheral blood lymphocyte subsets of healthy dogs. [Res Vet Sci. 136: 200-8.](#)
26. Milhau, N. *et al.* (2020) *In vitro* evaluations on canine monocyte-derived dendritic cells of a nanoparticles delivery system for vaccine antigen against *Echinococcus granulosus*. [PLoS One. 15 \(2\): e0229121.](#)
27. Sheng, R. *et al.* (2023) Prognostic significance of CD25 expression in dogs with a noninvasive diagnosis of B-cell lymphoma treated with CHOP chemotherapy. [Vet Comp Oncol. 21 \(1\): 28-35.](#)
28. Benavides, F.P. *et al.* (2021) Intrathecal Transplantation of Autologous and Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Dogs. [Cell Transplant. 30: 9636897211034464.](#)
29. Stokol, T. *et al.* (2024) Flow cytometric-based detection of CD80 is a useful diagnostic marker of acute myeloid leukemia in dogs. [Front Vet Sci. 11: 1405297.](#)
30. Rogato, F. *et al.* (2024) Leukemia cutis as a prominent clinical sign in a dog with acute myeloid leukemia. [Vet Clin Pathol. 53 \(4\): 448-457.](#)

Storage This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

Guarantee 12 months from date of despatch

Acknowledgements This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com

Health And Safety Information Material Safety Datasheet documentation #10041 available at: <https://www.bio-rad-antibodies.com/SDS/MCA1044A647>
10041

Regulatory For research purposes only

Related Products

Recommended Negative Controls

[RAT IgG2a NEGATIVE CONTROL:Alexa Fluor® 647 \(MCA6005A647\)](#)

[RAT IgG2a NEGATIVE CONTROL:Alexa Fluor® 647 \(MCA1212A647\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

'M407952:221010'

Printed on 25 Mar 2025